Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
modulates endocannabinoid system
|
| gptkbp:brand |
not yet marketed
|
| gptkbp:clinical_trial |
gptkb:Europe
gptkb:United_States high Phase 1 Phase 2 Phase 3 |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:developed_by |
gptkb:Alkermes
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALX-0714
|
| gptkbp:indication |
anxiety disorders
mood disorders |
| gptkbp:ingredients |
C22 H24 N2 O3 S
|
| gptkbp:invention |
patented
|
| gptkbp:is_tested_for |
clinical trials
|
| gptkbp:is_used_for |
treatment of schizophrenia
|
| gptkbp:lifespan |
12 hours
|
| gptkbp:manager |
oral
|
| gptkbp:metabolism |
liver
|
| gptkbp:receives_funding_from |
government grants
pharmaceutical companies private investors |
| gptkbp:research_focus |
psychiatric disorders
preclinical |
| gptkbp:safety_features |
under investigation
|
| gptkbp:side_effect |
anxiety
dizziness fatigue headache nausea irritability restlessness insomnia constipation dry mouth nervousness weight gain sweating mood swings blurred vision tremors increased appetite palpitations |
| gptkbp:social_structure |
sulfonamide derivative
|
| gptkbp:target_audience |
adults
elderly patients with treatment-resistant conditions |
| gptkbp:targets |
cannabinoid receptors
|
| gptkbp:year_created |
gptkb:2015
|
| gptkbp:bfsParent |
gptkb:Ablynx
|
| gptkbp:bfsLayer |
4
|